Quick Answer
Rein Therapeutics, Inc. reported R&D Expense of $11.03 million for fiscal year 2025.
Rein Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.03M | -22.6% |
| 2024 | $14.25M | +257.0% |
| 2023 | $3.99M | -77.8% |
| 2022 | $17.97M | +5.6% |
| 2021 | $17.01M | +52.3% |
| 2020 | $11.17M | -36.8% |
| 2019 | $17.66M | -4.3% |
| 2018 | $18.45M | +29.6% |
| 2017 | $14.24M | +38.6% |
| 2016 | $10.28M | +31.2% |
| 2015 | $7.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.68M | -54.8% | -60.8% |
| June 30, 2025 | $4.29M | +14.7% | +40.5% |
| March 31, 2025 | $3.05M | -11.8% | -17.9% |
| September 30, 2024 | $3.72M | +16818.2% | -0.5% |
| June 30, 2024 | $3.74M | +1900.5% | +8.0% |
| March 31, 2024 | $3.46M | +91.3% | +15640.9% |
| September 30, 2023 | $22.0K | -99.5% | -88.2% |
| June 30, 2023 | $187.0K | -96.6% | -89.7% |
- Rein Therapeutics, Inc. showed a decrease of -22.6% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Rein Therapeutics, Inc.’s r&d expense has grown by 40.8% (from $7.83 million to $11.03 million).
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: